依诺利单抗（OPi）。
Inolimomab (OPi).
作者信息
Winkler Michael
机构信息
Klinik für Visceral- und Transplantationschirurgie, Transplantationschirurgie, Medizinische Hochschule Hannover, Germany.
出版信息
Curr Opin Investig Drugs. 2002 Oct;3(10):1464-7.
PMID:12431019
Abstract
OPi (formerly Orphan Pharma International) is developing inolimomab, an anti-interleukin-2 receptor (CD25) monoclonal antibody for the potential treatment of acute graft versus host disease. As of April 2001, inolimomab was undergoing phase II/III clinical trials.
摘要
OPi（前身为孤儿药国际公司）正在研发inolimomab，一种抗白细胞介素-2受体（CD25）单克隆抗体，用于潜在治疗急性移植物抗宿主病。截至2001年4月，inolimomab正在进行II/III期临床试验。
相似文献
1
Inolimomab (OPi).依诺利单抗（OPi）。
Curr Opin Investig Drugs. 2002 Oct;3(10):1464-7.
2
Inolimomab. Anti-CD25 monoclonal antibody B-B10, anti-interleukin-2 receptor monoclonal antibody B-B10, B-B10, BT 563, Leukotac.
Drugs R D. 1999 Jan;1(1):81-4. doi: 10.2165/00126839-199901010-00027.
3
Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.
Biol Blood Marrow Transplant. 2006 Nov;12(11):1135-41. doi: 10.1016/j.bbmt.2006.06.010.
4
Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.英利莫单抗治疗皮质类固醇难治性急性移植物抗宿主病的最新经验。
Biol Blood Marrow Transplant. 2013 Mar;19(3):435-9. doi: 10.1016/j.bbmt.2012.11.012. Epub 2012 Nov 20.
5
[Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].[HLA单倍型相合骨髓移植（BMT）中急性移植物抗宿主病预防新方案的临床研究]
Zhonghua Xue Ye Xue Za Zhi. 2003 Aug;24(8):416-9.
6
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease.英欧联单抗的暴露-效应群体模型，英欧联单抗是一种用于急性移植物抗宿主病一线治疗的单克隆抗体。
Clin Pharmacokinet. 2007;46(5):417-32. doi: 10.2165/00003088-200746050-00004.
7
A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.一项比较依洛尤单抗与常规治疗在类固醇耐药性急性移植物抗宿主病中的 3 期随机试验。
Blood. 2017 Feb 2;129(5):643-649. doi: 10.1182/blood-2016-09-738625. Epub 2016 Nov 29.
8
Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD.儿童和青少年非亲缘骨髓移植后的长期生存以及采用CD25阻断进行预防移植物抗宿主病的靶向治疗。
Klin Padiatr. 2004 May-Jun;216(3):169-75. doi: 10.1055/s-2004-822630.
9
Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.达利珠单抗，一种治疗类固醇难治性急性移植物抗宿主病的有效药物。
Br J Haematol. 2006 Nov;135(3):382-5. doi: 10.1111/j.1365-2141.2006.06321.x. Epub 2006 Sep 19.
10
Clinical utility of rituximab in chronic graft-versus-host disease.利妥昔单抗在慢性移植物抗宿主病中的临床应用
Ann Pharmacother. 2009 Feb;43(2):316-21. doi: 10.1345/aph.1L386. Epub 2009 Feb 3.
Zotero 插件